Mainz Biomed B.V. (MYNZ)
Mainz Biomed B.V. Statistics
Share Statistics
Mainz Biomed B.V. has 2.22M shares outstanding. The number of shares has increased by -88.04% in one year.
| Shares Outstanding | 2.22M |
| Shares Change (YoY) | -88.04% |
| Shares Change (QoQ) | -90.85% |
| Owned by Institutions (%) | 1.03% |
| Shares Floating | 2.11M |
| Failed to Deliver (FTD) Shares | 26 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 41.31K, so 1.86% of the outstanding shares have been sold short.
| Short Interest | 41.31K |
| Short % of Shares Out | 1.86% |
| Short % of Float | 1.97% |
| Short Ratio (days to cover) | 0.3 |
Valuation Ratios
The PE ratio is -28.66 and the forward PE ratio is -0.56. Mainz Biomed B.V.'s PEG ratio is 2.14.
| PE Ratio | -28.66 |
| Forward PE | -0.56 |
| PS Ratio | 841.61 |
| Forward PS | 0.3 |
| PB Ratio | 231.95 |
| P/FCF Ratio | -31.62 |
| PEG Ratio | 2.14 |
Enterprise Valuation
Mainz Biomed B.V. has an Enterprise Value (EV) of 19.19M.
| EV / Earnings | -0.73 |
| EV / Sales | 21.43 |
| EV / EBITDA | -0.77 |
| EV / EBIT | -0.72 |
| EV / FCF | -0.81 |
Financial Position
The company has a current ratio of 0.97, with a Debt / Equity ratio of 2.28.
| Current Ratio | 0.97 |
| Quick Ratio | 0.91 |
| Debt / Equity | 2.28 |
| Total Debt / Capitalization | 69.55 |
| Cash Flow / Debt | -2.96 |
| Interest Coverage | -32.91 |
Financial Efficiency
Return on equity (ROE) is -8.09% and return on capital (ROIC) is -249.72%.
| Return on Equity (ROE) | -8.09% |
| Return on Assets (ROA) | -1.71% |
| Return on Capital (ROIC) | -249.72% |
| Revenue Per Employee | $13,776.6 |
| Profits Per Employee | $-404,549.65 |
| Employee Count | 65 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.63 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -88.45% in the last 52 weeks. The beta is 0.34, so Mainz Biomed B.V.'s price volatility has been higher than the market average.
| Beta | 0.34 |
| 52-Week Price Change | -88.45% |
| 50-Day Moving Average | 5.44 |
| 200-Day Moving Average | 11.67 |
| Relative Strength Index (RSI) | 42.98 |
| Average Volume (20 Days) | 214.73K |
Income Statement
In the last 12 months, Mainz Biomed B.V. had revenue of 895.48K and earned -26.3M in profits. Earnings per share was -1.62.
| Revenue | 895.48K |
| Gross Profit | 509.66K |
| Operating Income | -26.64M |
| Net Income | -26.3M |
| EBITDA | -25.01M |
| EBIT | -26.64M |
| Earnings Per Share (EPS) | -1.62 |
Balance Sheet
The company has 7.07M in cash and 7.42M in debt, giving a net cash position of -349.86K.
| Cash & Cash Equivalents | 7.07M |
| Total Debt | 7.42M |
| Net Cash | -349.86K |
| Retained Earnings | -69.33M |
| Total Assets | 15.41M |
| Working Capital | -257.15K |
Cash Flow
In the last 12 months, operating cash flow was -21.94M and capital expenditures -1.9M, giving a free cash flow of -23.84M.
| Operating Cash Flow | -21.94M |
| Capital Expenditures | -1.9M |
| Free Cash Flow | -23.84M |
| FCF Per Share | -1.47 |
Margins
Gross margin is 56.91%, with operating and profit margins of -2.98K% and -2.94K%.
| Gross Margin | 56.91% |
| Operating Margin | -2.98K% |
| Pretax Margin | -2.94K% |
| Profit Margin | -2.94K% |
| EBITDA Margin | -2.79K% |
| EBIT Margin | -2.98K% |
| FCF Margin | -2.66K% |
Dividends & Yields
MYNZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -34.03% |
| FCF Yield | -225.42% |
Analyst Forecast
The average price target for MYNZ is $14, which is 194.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $14 |
| Price Target Difference | 194.1% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Dec 3, 2024. It was a backward split with a ratio of 1:40.
| Last Split Date | Dec 3, 2024 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -15.21 |
| Piotroski F-Score | 3 |